Select Publications
Journal articles
2019, 'Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015', Medical Journal of Australia, 210, pp. 269 - 275, http://dx.doi.org/10.5694/mja2.50006
,2019, 'Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps', HIV Medicine, 20, pp. 3 - 11, http://dx.doi.org/10.1111/hiv.12708
,2019, 'FRI-200-Spend less get more;cost effectiveness of various models of care in hepatitis C treatment', Journal of Hepatology, 70, pp. e479 - e479, http://dx.doi.org/10.1016/s0618-8278(19)30945-4
,2018, 'Smoking and HIV: What are the risks and what harm reduction strategies do we have at our disposal?', AIDS Research and Therapy, 15, http://dx.doi.org/10.1186/s12981-018-0213-z
,2018, 'Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience', Journal of Viral Hepatitis, 25, pp. 1287 - 1297, http://dx.doi.org/10.1111/jvh.12943
,2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018', Journal of Virus Eradication, 4, pp. 143 - 159, http://dx.doi.org/10.1016/s2055-6640(20)30260-0
,2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', J Virus Erad, 4, pp. 143 - 159, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892678/
,2018, 'Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, 66, pp. 1846 - 1857, http://dx.doi.org/10.1093/cid/cix1108
,2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', Journal of Virus Eradication, 4, pp. 143 - 159
,2018, 'Combination ART: are two drugs as good as three?', The Lancet, 391, pp. 817 - 819, http://dx.doi.org/10.1016/S0140-6736(18)30008-4
,2018, 'Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy', AIDS, 32, pp. 357 - 361, http://dx.doi.org/10.1097/QAD.0000000000001688
,2018, 'Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial', Antiviral Therapy, 23, pp. 21 - 32, http://dx.doi.org/10.3851/IMP3171
,2018, 'Towards a universal second-line fixed-dose combination ART', The Lancet HIV, 5, pp. e3 - e5, http://dx.doi.org/10.1016/S2352-3018(17)30180-7
,2018, 'Outcomes of direct-acting antiviral therapy for chronic hepatitis C following unrestricted access in Australia: Real-world outcomes from the state of South Australia', Journal of Hepatology, 68, pp. S265 - S265, http://dx.doi.org/10.1016/s0168-8278(18)30743-8
,2017, 'Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study', PLoS Medicine, 14, pp. e1002424, http://dx.doi.org/10.1371/journal.pmed.1002424
,2017, 'The impact of changes in HIV management guidelines on time to treatment initiation in Australia', HIV Medicine, 18, pp. 701 - 703, http://dx.doi.org/10.1111/hiv.12504
,2017, 'Long-acting injectable ART: next revolution in HIV?', The Lancet, 390, pp. 1468 - 1470, http://dx.doi.org/10.1016/S0140-6736(17)31962-1
,2017, 'The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.', BMC Medicine, 15, pp. 145, http://dx.doi.org/10.1186/s12916-017-0888-3
,2017, 'Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners’ attitudes', Drug and Alcohol Dependence, 177, pp. 67 - 70, http://dx.doi.org/10.1016/j.drugalcdep.2017.03.023
,2017, 'Tobacco harm reduction with vaporised nicotine (THRiVe): The study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke', International Journal of Environmental Research and Public Health, 14, http://dx.doi.org/10.3390/ijerph14070799
,2017, 'Body composition substudy of the SECOND-LINE study – Author's reply', The Lancet HIV, 4, pp. e240, http://dx.doi.org/10.1016/S2352-3018(17)30093-0
,2017, 'Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration', EBioMedicine, 18, pp. 225 - 235, http://dx.doi.org/10.1016/j.ebiom.2017.03.024
,2017, 'HIV care in Yangon, Myanmar; successes, challenges and implications for policy', AIDS Research and Therapy, 14, pp. 10, http://dx.doi.org/10.1186/s12981-017-0137-z
,2017, 'Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol', BMC Infectious Diseases, 17, pp. 35, http://dx.doi.org/10.1186/s12879-016-2125-7
,2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study', The Lancet HIV, 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8
,2017, 'CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy', Antiviral Therapy, 22, pp. 659 - 668, http://dx.doi.org/10.3851/IMP3155
,2017, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines', Journal of Virus Eradication, 3, pp. 168 - 184, http://dx.doi.org/10.1016/s2055-6640(20)30338-1
,2016, 'Sexual transmission of HIV and the law: An Australian medical consensus statement', Medical Journal of Australia, 205, pp. 409 - 412, http://dx.doi.org/10.5694/mja16.00934
,2016, 'CD4+ T follicular helper and IgA+ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals', Frontiers in Immunology, 7, pp. 438, http://dx.doi.org/10.3389/fimmu.2016.00438
,2016, 'Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study', AIDS Research and Human Retroviruses, 32, pp. 841 - 850, http://dx.doi.org/10.1089/aid.2015.0331
,2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', The Lancet HIV, 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7
,2016, 'Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART', Journal of Antimicrobial Chemotherapy, 71, pp. 1056 - 1062, http://dx.doi.org/10.1093/jac/dkv427
,2016, 'Tenofovir alafenamide: safer, but questions remain', The Lancet HIV, 3, pp. e148 - e149, http://dx.doi.org/10.1016/S2352-3018(16)00039-4
,2016, 'Reviewer acknowledgement.', AIDS Res Ther, 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8
,2016, 'Novel antiretroviral agents and universal access to HIV care', The Lancet HIV, 3, pp. e2 - e3, http://dx.doi.org/10.1016/S2352-3018(15)00244-1
,2016, 'Which HIV patients should be screened for osteoporosis: An international perspective', Current Opinion in HIV and AIDS, 11, pp. 268 - 276, http://dx.doi.org/10.1097/COH.0000000000000269
,2016, 'Reviewer acknowledgement.', AIDS Res Ther, 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8
,2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 ))', PLoS ONE, 10, pp. e0140623, http://dx.doi.org/10.1371/journal.pone.0140623
,2015, 'The LATTE study: A provocative brew', The Lancet Infectious Diseases, 15, pp. 1116 - 1117, http://dx.doi.org/10.1016/S1473-3099(15)00224-8
,2015, 'Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)', BMC Infectious Diseases, 15, pp. 326, http://dx.doi.org/10.1186/s12879-015-1051-4
,2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5
,2015, 'Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis', EBioMedicine, 2, pp. 706 - 712, http://dx.doi.org/10.1016/j.ebiom.2015.05.012
,2015, 'HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD)', HIV Medicine, 16, pp. 152 - 160, http://dx.doi.org/10.1111/hiv.12188
,2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', PLoS ONE, 10, pp. e0118228, http://dx.doi.org/10.1371/journal.pone.0118228
,2015, 'Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis', The Lancet HIV, 2, pp. e42 - e51, http://dx.doi.org/10.1016/S2352-3018(14)00061-7
,2015, 'Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia', Antiviral Therapy, 20, pp. 255, http://dx.doi.org/10.3851/IMP2822
,2015, 'Is it time to rethink syphilis control?', Clinical Infectious Diseases, 60, pp. 325 - 326, http://dx.doi.org/10.1093/cid/ciu813
,2015, 'Recent trends in early stage response to combination antiretroviral therapy in Australia', Antiviral Therapy, 20, pp. 131 - 139, http://dx.doi.org/10.3851/IMP2774
,2014, 'Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial', The Lancet, 384, pp. 1942 - 1951, http://dx.doi.org/10.1016/S0140-6736(14)61170-3
,2014, 'A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection', AIDS Research and Therapy, 11, http://dx.doi.org/10.1186/1742-6405-11-35
,